Targeted DNA Modification: A New Paradigm to Exploit DDR Defects in Glioma and Beyond…

Time: 3:30 pm
day: Conference Day 2


  • Discuss Modifi Bio’s development candidate which selectively targets MGMT-deficient cancers
  • Review data suggesting efficacy of these molecules across a range of brain tumor models, as a monotherapy and in combination with other agents
  • Highlights of Modifi’s biomarker strategy to enrich for MGMT- gliomas with acquired MMR mutations in a phase 0/I trial